Zim Laboratories Limited — Important, 10-02-2025: General Updates

**FINANCIAL HIGHLIGHTS**

Total Operating Income for Q3 FY25 remained stable at ₹963 Mn, reflecting a 4.5% QoQ growth. EBITDA increased to ₹133 Mn, representing a 22% QoQ growth, with margins improving to 13.8% from 13.1%. Profit After Tax (PAT) also saw a significant rise, standing at ₹40 Mn with a margin of 4.2%, marking a 68% QoQ increase from ₹24 Mn.

In the first nine months of FY25, Total Operating Income grew by 8.3% YoY to ₹2,703 Mn, driven by strong performance in innovative products, contributing ₹477 Mn in revenue—a remarkable 83% YoY increase. EBITDA for 9M FY25 reached ₹332 Mn with margins at 12.3%, up from 11.7% in the previous year. PAT was reported at ₹73 Mn, impacting margin at 2.7%.

**STRATEGIC INITIATIVES AND GROWTH DRIVERS**

ZIM Laboratories is nearing completion of two major capex projects: the Urology Suite and Nutraceutical Suite, poised for completion by Q4 FY25. The innovative products segment, including New Innovative Products (NIP) and Oral Thin Films (OTF), is gaining traction, with significant licensing milestone payments contributing to revenue growth.

**BUSINESS DEVELOPMENTS**

A new scientific office has been established in the UAE to enhance marketing and registrations in the MENA region. The expansion of the Business Development team is underway to solidify ZIM's presence in key markets.

**MARKET POSITION AND COMPETITIVE ADVANTAGE**

ZIM’s robust operational framework, combined with an integrated business model and diverse product portfolio, positions the company well against competitors. The emphasis on high-value products highlights its strategic shift away from lower-margin offerings.

**INVESTOR IMPLICATIONS**

With steady income growth, improved margins, and strategic initiatives aligning with market demands, ZIM Laboratories presents a positive outlook for investors. Continued focus on innovative products and market expansion could drive significant growth in the upcoming quarters.